Skip to content

Clinical Performance Evaluation of Intelligenome CRISPR-TB Blood Test

Clinical Performance Evaluation of Intelligenome CRISPR-TB Blood Test - REQA_24007_IGDX

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00037407
Enrollment
180
Registered
2025-07-11
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycobacterium tuberculosis infection

Interventions

Group 1: Testing of blood samples for Mtb infection with the investigational device. Group 2: Testing of sputum samples (from the same group) for Mtb infection with the comparator device.

Sponsors

IGDX, Inc. DBA Intelligenome, Inc.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Agree with the content and able to sign the Informed Consent Form. Has clinical signs and symptoms typically associated with active TB disease.

Exclusion criteria

Exclusion criteria: Has medical emergency Pregnancy Insufficient physical or mental health condition Having TB treatment for longer than 3 days before enrollment Impaired cognitive function

Design outcomes

Primary

MeasureTime frame
Positive Percent Agreement (Diagnostic Sensitivity) Negative Percent Agreement (Diagnostic Specificity)

Secondary

MeasureTime frame
Positive predictive value (PPV), Negative predictive value (NPV), Likelihood ratio (LR)

Countries

Germany

Contacts

Public ContactHakan Inan

Requalite GmbH

Hakan@requalite.com+49 89 32800304

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026